Peptide Comparison
IGF-1 DES vs Hulk Stack
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than Hulk Stack (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| IGF-1 DES | Hulk Stack | |
|---|---|---|
| Class | IGF-1 analog (truncated); anabolic | GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity | Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. |
| Route | SC / IM | SC injection (typically 2-3 separate sites) |
| Half-life | ~30 min | CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs |
| Dosage (research) | 50-150 mcg SC near target muscle | Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal |
| Research depth | 25 indexed | — |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Hypoglycemia; localized tissue growth; theoretical cancer risk | Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick IGF-1 DES or Hulk Stack?
IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than Hulk Stack (Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between IGF-1 DES and Hulk Stack?
IGF-1 DES is classed as IGF-1 analog (truncated); anabolic; Hulk Stack is classed as GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Reported mechanism: IGF-1 DES, Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity; Hulk Stack, Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. Reported half-life: IGF-1 DES, ~30 min; Hulk Stack, CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs. Routes in published studies: IGF-1 DES, SC / IM; Hulk Stack, SC injection (typically 2-3 separate sites).
Which has stronger evidence, IGF-1 DES or Hulk Stack?
IGF-1 DES and Hulk Stack sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 DES is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 25 indexed studies. Hulk Stack is graded Anecdotal, with 3 cited sources on its reference page.
Which is more accessible, IGF-1 DES or Hulk Stack?
Neither IGF-1 DES nor Hulk Stack is an FDA-approved drug. Catalog status: IGF-1 DES, Research Chemical; Hulk Stack, Compounding Restricted.
Are IGF-1 DES and Hulk Stack ever combined?
IGF-1 DES and Hulk Stack appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…